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*Nocardia* spp. are environmental bacteria that cause pulmonary infections similar to tuberculosis, and even disseminated disease ([@B1], [@B2]). *Nocardia farcinica* causes invasive infections with cerebral involvement (55%) and high mortality (35%) ([@B1], [@B3]). In Spain, resistance to trimethoprim/sulfamethoxazole (the cornerstone of treatment) in *N. farcinica* runs at 45% ([@B4]). Linezolid, with excellent bioavailability, provides an efficient alternative ([@B1], [@B5]). From childhood, patients with cystic fibrosis (CF) suffer frequent lung infections. From these patients, two *N. farcinica* strains (drug pattern type V \[[@B6]\]) highly resistant to trimethoprim/sulfamethoxazole and linezolid (MICs ≥32:608 and ≥256 µg/mL, respectively), were sequenced for a better understanding of their genetic background.

Paired-end libraries (Nextera-XT DNA library preparation kit, Illumina 1.9), were adapted and sequenced at 2 × 150 using Illumina NextSeq500. After quality control analysis involving fastQC v0.11.3 (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>) and Trimmomatic v0.36 software ([@B7]), 3.1 million to 3.6 million paired-end reads of 50 to 151 bp were retrieved. Read assembly was performed using SPAdes v3.8.0 software ([@B8]) (kmer = 77), and the quality was evaluated using QUAST software ([@B9]).

The draft genomes of the strains, named CNM20080921 and CNM20091955, were both 5.8 Mbp long and had a G+C content of 70.63% (178 and 113 contigs of ≥500 bp; maximum, 674,734 and 1,141,487 bp; *N*~50~ value, 167,048 and 453,514 bp). Analysis using ANI software ([@B10]) revealed them to show 99.98% sequence similarity, and 99.28% similarity to *N. farcinica* NCTC11134 (GenBank accession number, NZ_LN868938). The assembled sequences were annotated using Prokka 1.12-beta software ([@B11]), which predicted 6,502 and 6,455 genes (6,428 and 6,381 protein-coding genes and 427 and 419 signal peptides, respectively), and 6 rRNAs, 67 tRNAs, and 1 transfer-messenger RNA (tmRNA) for both strains.

The following potential resistance genes (<https://ardb.cbcb.umd.edu/>, <http://nocardia.nih.go.jp>) were detected in both strains: *bmr*, *stp*, *marR*, *mtdL*, *norM*, *emrB*, *emrY*, FAR-1, *ampC*, *aacA-aphD*, *aph(3′)*, *ant1*, *neo*, *fstH*, *htpX*, *murA*, *ermH*, *tetA*, *tetC*, *tetR*, *mtdH*, *dfrA26*, *vanW*, *bac*, *qacA*, *sugE*, *acr3*, *ohrA*, *drrA*, *drrB*, *drrC*, *carA*, *merR*, and *yfmO*; *rmlA* was detected in CNM20091955 only. Detected resistant genes by PCR sequencing of boiled extract of both strains ([@B12]), e.g., *int1-3*, *sul1-2*, *ermTR*, *ermB*, and *tetO* (and *mefO* for CNM20080921), were not detected by srst2 ([@B13]) and ARGANNOT ([@B14]) software (only *int1*, *clmA*, and FAR-1 were detected). Neither of the two 23S rRNA copies showed the G2576T mutation (*Escherichia coli* numbering) allowing linezolid resistance. However, one allele of CNM20080921 showed the change G2608A. Mobile element-related sequences, such as *IS*5376/*IS*6110, *tnp*R (resolvase) guaA (integration hot spot), three IS3-family transposases, and two transposases from *Tn*916, were identified in both strains.

Similar virulence contents were detected such as mammalian cell entry protein, ESX-1, and others (*fbpA*, *fbpB*, *fbpC*, *sodC*, *katA*, *katE*, *katG*, *ideR*, *nbtB*, *nbtD*, *nbtE*, *nbtF*, *nbtG*, *nbtS*, *aphC*, *aphD*, *narG*, *oxyR*, *ndk*, *ptpA*, *tlyA*, and *tlyC*) ([@B15]). The biosynthetic gene clusters for CNM20080921 and CNM20091955 were 7 and 9 nonribosomal peptide synthases, 4 and 5 polyketide synthases, 5 terpene cyclases, and ectoine and nocobactin genes, respectively ([@B16]). Clustered regularly interspaced short palindromic repeats (CRISPR) (12 and 11, respectively) were found in each one. In both strains, the same incomplete prophage (7.4 Kb, 71.39% G+C) was identified ([@B17]).

Given their exposure to viral/bacterial infections and frequent antimicrobial treatment, the pulmonary microbiomes of patients with CF are fragile. If lung transplantation is to be successful in such patients, the surveillance of *Nocardia* species is needed (see reference [@B18]).
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This whole-genome shotgun project has been deposited at DDBJ/ENA/GenBank under the accession numbers [NXEH00000000](http://www.ncbi.nlm.nih.gov/nuccore/NXEH00000000) and [NXEG00000000](http://www.ncbi.nlm.nih.gov/nuccore/NXEG00000000) for CNM20080921 and CNM20091955, respectively. The versions described in this paper are versions NXEH01000000 and NXEG01000000.
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